NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP
Biomerica, Inc. BMRA
15 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$5.3M
▼ 1.9% vs FY2023
EPS · FY24
$-2.16
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-93.0%
Net margin · FY24
-93.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.3M
Revenue, FY2024 · full 15-year series below
Revenue
Net income
The company lost 94 cents on every revenue dollar this year.
Per share
USD -2.16
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-93.0%
Return on equity, FY2024
ROE
Operating margin-96.7%
Net margin-93.6%
Return on assets-65.4%
Each USD of equity lost 93 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−4.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−34.5%
−4.5%
+0.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2024
Change, 5 years+89.3%
Change, 10 years+131.2%
The share count grew 89% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 5.9M
total assets, end of FY2024
Total assetsUSD 5.9M
EquityUSD 4.1M
CashUSD 2.4M
Current ratio2.80×
Equity funds 69% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
EBITDA $B
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
−0.0
−0.0
−0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
EPS, diluted $
−2.16
−2.84
−0.50
−0.36
−0.62
−0.26
−0.26
−0.17
−0.11
−0.20
−0.04
−0.03
0.07
0.08
0.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−93.0
−65.3
−71.2
−51.6
−63.5
−29.4
−57.6
−33.3
−18.7
−27.7
−5.8
−3.7
9.9
11.8
3.6
Shares out B
0.00
0.00
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
60 of 60
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed